Titan Medical Inc (TMDIF)

[66Mustang]

Rocko, please don't forget to mention the following when talking about competition, especially in the single port realm:

"da Vinci Xi can perform single port surgery as well [61,97]. When da Vinci Xi is being used for single port surgery, only two of the three instrument arms are used. The instrument arms cross over in the trocar such that the right instrument arm controls the left end effector, and the left arm the right end effector [61]."

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwi25p6isMTxAhVHVs0KHXfUBmw4FBAWegQIBRAD&url=https%3A%2F%2Fres.mdpi.com%2Fd_attachment%2Frobotics%2Frobotics-09-00042%2Farticle_deploy%2Frobotics-09-00042-v2.pdf&usg=AOvVaw3pnU-4hSfKv9_IyOm1r51J

The very unnatural manipulation of end effectors by surgeons using the current Xi SP system could well be a factor in suppressing SP sales to date, allowing for a competitor with a human-friendly user interface to step in and gain accolades and market share very quickly upon release to the market. I think Medtronic would like to be the supplier, considering (as you noted) that SP is already an $8B value with the only SP offering being crossed up. Imagine the potential market share of a system that surgeons WANT to use!


Message in reply to:
Titan is developing an endoluminal prototype w Titan IP in it.

Reminder for anyone not paying attention: in order for anyone to compete w ISRG they will need multi port, single port and endoluminal. So what does Medtronic have, they have a multi port system called Hugo, they will need an endoluminal system (we will call this milestone 4 prototype) and they will need a single port system (Enos)

Auris (endoluminal - one indication) went for $5.7B. The software science project vicarious w NO PATENT PROTECTION is a POS knock off single port system valued at $1.1B (btw it’s single indication is hernias). ISRG SP - single indication - has added over $8B in MC to ISRG.

IT is very easy to get to a multi billion dollar valuation w Titan considering they will deliver an endoluminal prototype w Titan IP, they have a next generation surgical robotic single port system, their IP will enhance second generation HUGO SYSTEM, they have a world class R&D team and one of the best IP portfolios in the surgical robotic space.